In a retrospective cohort study that recruited 37,857 IBD patients, among whom 36 developed incident COVID-19, TNF antagonists were not associated with an increased risk of SARS-CoV-2 infection [88]. The gene discussed is TNF; the disease is inflammatory bowel disease.